The Cancer Profile™© is based on the premise that detectable biochemical changes occur in the human body during its transformation into a cancerous state. It is composed of 7 tests: HCG (human chorionic gonadotropin) chemiluminescence assay serum and HCG urine quantitative tests (American Metabolic Laboratories is the one and only clinical laboratory performing quantitative analysis for urine in the entire world). The PHI (phosphohexose isomerase enzyme); CEA (carcinoembryonic antigen); GGTP (gamma-glutamyltranspeptidase); TSH (thyroid-stimulating hormone); and DHEA-S (dehydroepiandrosterone sulfate).
Dr. Schandl developed his battery of tests after a great deal of reading, testing and experimentation at the Howard Hughes Research Institute in Miami and at local hospitals in South Florida. He has observed marker elevations in patients as many as 10 to 12 years prior to diagnosis. Knowing that the developmental process of cancer takes 10 to12 years, one may be able to detect the very beginning of cancer, allowing plenty of time to make lifestyle adjustment corrections in order to avoid possibly catastrophic consequences. It should be noted that the CA Profile™© is excellent not only for early detection, but also clinical laboratory follow-up and monitoring disease reduction or progression.
While numerous studies have confirmed that HCG levels are elevated in the presence of cancer cells in the body, a caveat in using HCG alone as a tumor marker is that it may be present in super-low quantities that cannot be detected, even by existing technology. Therefore, the Cancer Profile™© includes other tumor markers as well. In other words, what one test may miss, the other(s) will usually detect.
Consider the fact that testing for HCG alone can result in approximately 30% false negative results. The entire Cancer Profile™© may miss only 10-15% cancer positive patients. Neither the HCG Urine nor serum alone or together is sufficient to detect or follow a cancer disease process.
In a study reported in 1987, the tumor marker CEA proved to be sensitive in cases of metastasized bone cancer, while PHI was elevated in cancers of other organs. However, when CEA and PHI were combined, overall sensitivity was increased considerably [Paulick, R., et al., Cancer Detect Prev, 1987, 10 (3-4): 197-203].
Studies have shown that, when testing patients who were known to have cancer, 68 percent showed elevated HCG levels. When the measurement was for the enzyme PHI, 80+ percent was detected. GGTP was elevated in 39 percent, and CEA was positive in 51 percent.
When combining specific tests and using more refined technology, Dr. Schandl's Cancer Profile™© produced more persuasive percentages; this panel has an impressive accuracy of 87-97%.
Looking at three cancer markers together (HCG, PHI, CEA), 221 positives in 240 breast cancer patients (92 percent) were detected. Of lung cancer patients, 127 of 129 (97 percent) were correctly diagnosed. And with colon cancer patients, 55 positives out of 59 patients (93 percent) were correctly identified.
Also included in the profile are the DHEA-S, TSH, and GGTP tests. These are peripherally related to cancer. The rationale is that people with either low thyroid activity, low adrenal activity, or abnormal GGTP results seem to be predisposed to cancer.
Other tests recommended (not included with the CA Profile):
|Test||What it tests for||Normal Range|
For men over the age of 40 to detect prostate cancer
|0.0 - 4.0 ng/mL. Values above 4.0 should be verified by a Free PSA test|
|Parathyroid hormone, for the detection of calcium depletion from the bones, e.g., osteoporosis||13 - 59 pg/mL|
|A marker for residual epithelial cancer of the ovary||Less than 35 U/mL|
|A breast cancer marker |
7.5 - 53.0 U/mL
|A test for gastric/pancreatic cancer||Less than 34 U/mL|
|(IGF-1) Human youth/longevity/growth/ strength/vigor hormone||Normal vary by age|
Study of a number of blood chemistries, e.g. sugar, cholesterol, kidney and liver function, etc. CBC, the Complete Blood Count is for red and white cells, lymphocytes, platelets, etc.
The Cancer Profile™© gives early warning signs, but it also can be used as a cancer marker test to monitor established, existing cancers. Retesting can demonstrate whether treatment regimens are working, and how they can be adjusted. The tests also are important to establish a benchmark prior to surgery. With a retest later, one can determine the surgery's success in removing the tumor.
This also is borne out by research. For example, a study in the Journal of Tumor Marker Oncology (Luthgens M., et al., 1992, 7 : 44) reports that men who had had their diseased prostates removed had distinctly lower levels of both PSA and HCG, compared with those patients with tumors remaining. Clearly, lower levels of these markers indicate a procedure's effectiveness.
The markers may also serve as a warning signal of the prospect for renewed problems. A Japanese study reported in 1992 that a fragment of beta HCG, elevated in patients with cervical cancer, showed decreased levels in 24 out of 28 patients following successful treatment. However, of the other patients whose HCG levels remained high, half subsequently relapsed. [Kinugasa, M., et al., Nippon Sanka Fujinka Gakkai Zasshi, Feb., 1992, 44(2): 188-94].
The regimen may be clear: Doctors don't have to "watch and wait" for signs of a relapse when an accurate determiner such as tumor marker levels can predict success or failure, or the need for medical intervention.
Clinical Data - General Survey
Call Us: 954-929-4814